CytomX Therapeutics (CTMX) Misses Q3 EPS by 4c

CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of ($0.09), $0.04 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $11.84 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
• Hewlett Packard Enterprise (HPE) call put ratio 2.2 calls to 1 put into quarter results
• Yext, Inc. (YEXT) Tops Q2 EPS by 4c